Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B
Keywords:
ucleoside analogues (NA), partial response, drug resistant variants, hepatitis, hepatitis b virusAbstract
Introduction: The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alone in maintaining virological, biochemical and histological responses and 2) to investigate the patterns of mutations in the reverse transcriptase and surface proteins of HBV with LAM and/or ADF-resistant in partially-responded chronic hepatitis B (CHB) patients.
Methods: The study group consisted of 186 chronic HBV carriers who were admitted to the Tehran Hepatitis Network from 2010 to 2013. We retrospectively selected 86 patients who partially responded to different nucleoside analogue regimens. After 48 weeks of therapy, five groups of patients were defined including eight Lamivudine (LAM) Group (I), 30 Adefovir (ADV) Group (II), 16 ADV add on LAM Group (III), 32 ADV+LAM Group (IV), and 100 controls (no therapy). Reverse transcriptase (RT) and surface genes were amplified and sequenced for mutational analysis.
Results: All groups showed differences between mean values for age, gender, alanine transaminase (ALT), aspartate transaminase (AST), and HBV DNA levels groups showed significant differences than other groups (p < 0.05). The mutation frequencies for groups were I (1.7%), II (1.39%), III (2.28%), IV (2.0%), and V (0.38%). T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies. Four new, unreported mutations were found.
Conclusion: Those patients who failed to respond in the first 48 weeks, whether they were receiving mono or combination therapy, should be tested genotypically, for the early modification of treatment.
References
Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003; 23(1): 39-46. doi:
1055/s-2003-37583. PMID: 12616449.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new
estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9. doi:
1016/j.vaccine.2011.12.116. PMID: 22273662.
Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis
B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;
(1): 241-4. doi: 10.1002/hep.510250144. PMID: 8985298.
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of
YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;
(6): 687-96. PMID: 12627352.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy
with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352(26): 2673-81.
PMID: 15987916.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil
for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348(9): 800-7.
PMID: 12606734.
Lok AS. The maze of treatments for hepatitis B. N Engl J Med. 2005; 352(26): 2743-6. doi:
1056/NEJMe058119. PMID: 15987924.
Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J
Hepatol. 2005; 43(6): 920-3. doi: 10.1016/j.jhep.2005.09.003. PMID: 16246449.
Tan YW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, et al. Natural YMDD-motif mutants affect clinical
course of lamivudine in chronic hepatitis B. World J Gastroenterol. 2015; 21(7): 2089-95. PMID:
, PMCID: PMC4326144.
Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by
determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic
hepatitis B. Hepatology. 2000; 32(5): 1078-88. doi: 10.1053/j.gastro.2006.09.020. PMID: 11050059.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy
with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;
(6): 1743-51. PMID: 17087951.
Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to
ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;
(1): 81-90. doi: 10.1053/j.gastro.2003.10.050. PMID: 14699490.
Yang J, Chen G, Chen X, Zhang H, Jiang D, Yang G. Initial combination anti-viral therapy with
lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on- chronic liver failure. Virol J. 2015; 12: 97. doi: 10.1186/s12985-015-0323-3. PMID: 26104153, PMCID:
PMC4501091.
Warner N, Locarnini S. Mechanisms of hepatitis B virus resistance development. Intervirology. 2014; 57(3- 4): 218-24. doi: 10.1159/000360940. PMID: 25034491.
Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B
virus during sequential therapy. Hepatology. 2006; 44(3): 703-12. doi: 10.1016/j.jhep.2005.10.018. PMID:
Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and
resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006; 44(2): 283-90. PMID:
Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in
lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006; 55(10): 1488- 95. doi: 10.1136/gut.2005.077099. PMID: 16461777, PMCID: PMC1856440.
Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, et al. Virological response and incidence of
adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther. 2006;
(6): 771-8. PMID: 17310821.
Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in
lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45(2): 307-13. doi:
1002/hep.21534. PMID: 17256746.
Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, et al. Lamivudine plus adefovir vs. entecavir in
HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int. 2012;
(7): 1179-85. doi: 10.1111/j.1478-3231.2012.02793.x. PMID: 22452737.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines
on the management of hepatitis B: a 2015 update. Hepatol Int. 2015. PMID: 26563120, PMCID:
PMC4722087.
Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, et al. A low viral load predicts a higher initial
virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. Gut Liver. 2010;
(4): 530-6. PMID: 21253304, PMCID: PMC3021611.
Sinn DH, Lee HIE, Gwak GY, Choi MS, Koh KC, Paik SW, et al. Virological response to adefovir
monotherapy and the risk of adefovir resistance. World J Gastroenterol. 2011; 17(30): 3526-30. PMID:
, PMCID: PMC3163251.
Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, et al. High rate of complete viral
suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin
Gastroenterol. 2011; 45(10): 900-5. doi: 10.1097/MCG.0b013e318224d64f. PMID: 21778896.
Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg- positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol. 2009; 50(4):
-83. doi: 10.1016/j.jhep.2008.10.033. PMID: 19231002.
Mahabadi M, Norouzi M, Alavian SM, Samimirad K, Azad TM, Saberfar E, et al. Drug-related mutational
patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic
HBV patients. Hepat Mon. 2013; 13(1): 6712. doi: 10.5812/hepatmon.6712. PMID: 23596461, PMCID:
PMC3626233.
Jazayeri SM, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, et al. HBV core sequence: definition of
genotype-specific variability and correlation with geographical origin. J Viral Hepat. 2004; 11(6): 488-501.
PMID: 15500549.
Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carroue-Durantel S, Villeneuve JP, et al.
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine
and adefovir. Hepatology. 2005; 41(6): 1391-8. PMID: 15915463.
Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, et al. Evolution of full-length HBV sequences
in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol.
; 52(4): 478-85. doi: 10.1016/j.jhep.2010.01.006. PMID: 20185198.
Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, et al. Unusual selection of rtA181V
HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.
Antivir Ther. 2006; 11(8): 1103-6. PMID: 17302381.
Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, et al. Randomised clinical trial: the benefit of
combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther. 2012;
(9): 1027-35. PMID: 22449251.
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial
treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17): 1256-63. PMID:
Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in
Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004; 19(11): 1276-82. PMID:
Pallier C, Rodriguez C, Brillet R, Nordmann P, Hzode C, Pawlotsky JM. Complex dynamics of hepatitis B
virus resistance to adefovir. Hepatology. 2009; 49(1): 50-9. doi: 10.1002/hep.22634. PMID: 19065672,
PMCID: PMC2956748.
Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, et al. The profile of mutational clusters
associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol. 2009; 50(3): 461- 70. doi: 10.1016/j.jhep.2008.07.038. PMID: 19041149.
Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, et al. rtL180M mutation of hepatitis B virus is
closely associated with frequent virological resistance to adefovir dipivoxil therapy. J Gastroenterol
Hepatol. 2012; 27(2): 300-5. PMID: 21777282.
Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in
the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients
with chronic hepatitis B. J Med Virol. 1999; 9(3): 270-6. PMID: 10502255.
Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, et al. The L80I substitution in the
reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance
and enhanced viral replication in vitro. Antimicrob Agents Chemother. 2007; 51(7): 2285-92. PMID:
, PMCID: PMC1913255.
Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, et al. Long-term outcomes of
add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic
hepatitis B. Hepatol Res. 2012; 42(12): 1168-74. doi: 10.1111/j.1872-034X.2012.01038.x. PMID:
Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in
Turkish patients with chronic hepatitis B. Int J Infect Dis. 2011; 15(10): 722-6. doi:
1016/j.ijid.2011.05.019. PMID: 21784687.
Torresi J. The virological and clinical significance of mutations in the overlapping envelope and
polymerase genes of hepatitis B virus. J Clin Virol. 2002; 25(2): 97-106. PMID: 12367644.
Warner N, Locarnini S. Can antiviral therapy for chronic hepatitis B enhance the progression to
hepatocellular carcinoma? Antivir Ther. 2009; 14(2): 139-42. PMID: 19430088.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
